Idiopathic pulmonary arterial hypertension: current state of play and new treatment modalities.
Research in pulmonary hypertension has led to exciting advances over the last decade, both in terms of understanding aetiology and expanding treatment options. This review highlights the current approach to classification and disease management. In particular, we review the significant data and recommendations on the use of prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase inhibitors and drug combinations.
Gibbs
J Simon R
JS
Hammersmith Hospital, Royal Brompton Hospital and Harefield NHS Trust, and Imperial College London, UK. s.gibbs@imperial.ac.uk
Broberg
Craig S
CS
Gatzoulis
Michael A
MA
D000959:Antihypertensive Agents / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D006328:Cardiac Catheterization; D004777:Environment; D020022:Genetic Predisposition to Disease; D006801:Humans; D006976:Hypertension, Pulmonary / Q000145:classification / Q000209:etiology / Q000628:therapy*; D009154:Mutation; D014662:Vasoconstrictor Agents / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents